novacodone oxycodone hydrochloride 80mg modified release tablet blister pack
mundipharma pty ltd - oxycodone hydrochloride, quantity: 80 mg - tablet, modified release - excipient ingredients: polyethylene oxide; magnesium stearate; hypromellose; indigo carmine; hyprolose; polysorbate 80; iron oxide yellow; macrogol 400 - novacodone is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. novacodone modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. novacodone is not indicated as an as-needed-(prn) analgesia.
novacodone oxycodone hydrochloride 40mg modified release tablet blister pack
mundipharma pty ltd - oxycodone hydrochloride, quantity: 40 mg - tablet, modified release - excipient ingredients: magnesium stearate; polyethylene oxide; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - novacodone is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. novacodone modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. novacodone is not indicated as an as-needed-(prn) analgesia.
novacodone oxycodone hydrochloride 20mg modified release tablet blister pack
mundipharma pty ltd - oxycodone hydrochloride, quantity: 20 mg - tablet, modified release - excipient ingredients: polyethylene oxide; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - novacodone is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. novacodone modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. novacodone is not indicated as an as-needed-(prn) analgesia.
novacodone oxycodone hydrochloride 10mg modified release tablet blister pack
mundipharma pty ltd - oxycodone hydrochloride, quantity: 10 mg - tablet, modified release - excipient ingredients: magnesium stearate; polyethylene oxide; titanium dioxide; hypromellose; hyprolose; macrogol 400 - novacodone is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long term treatment. novacodone modified release tablet is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. novacodone is not indicated as an as-needed-(prn) analgesia.
trusopt dorzolamide 20mg/ml (as hydrochloride) eye drops bottle
mundipharma pty ltd - dorzolamide hydrochloride, quantity: 22.26 mg/ml (equivalent: dorzolamide, qty 20 mg/ml) - eye drops, solution - excipient ingredients: mannitol; sodium citrate dihydrate; benzalkonium chloride; hyetellose; water for injections; sodium hydroxide - trusopt eye drops are indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open- angle glaucoma.
nyxoid naloxone hydrochloride dihydrate 2.2 mg/actuation nasal spray vial
mundipharma pty ltd - naloxone hydrochloride dihydrate, quantity: 2.2 mg/actuation - spray, nasal - excipient ingredients: sodium chloride; hydrochloric acid; sodium citrate dihydrate; nitrogen; sodium hydroxide; purified water - nyxoid is intended as part of the emergency treatment for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in:,? the home or other non medical setting,? a health facility setting,for this reason, nyxoid should be carried by persons at risk of, or likely to witness such events.,nyxoid is indicated in adults and children.
tenopt 0.5%
mundipharma pty ltd - timolol -
tenopt 0.25%
mundipharma pty ltd - timolol -
mst continus suspension 60 mg
mundipharma pharmaceuticals limited - morphine - prolonged-release granules for oral suspension - 60 milligram(s) - natural opium alkaloids; morphine
mst continus suspension 30 mg
mundipharma pharmaceuticals limited - morphine - prolonged-release granules for oral suspension - 30 milligram(s) - natural opium alkaloids; morphine